A
Audentes Therapeutics
Biotech & Life Sciences · San Francisco, United States · Founded 2013 · IPO 2016 Unicorn
Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Global footprint
Where Audentes Therapeutics has talent and traffic
Patent intelligence
$4M patent portfolio · 7 active families
Where Audentes Therapeutics concentrates vs peers
Each axis is a top-10 topic across Audentes Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Sentiment on X
What X is saying about Audentes Therapeutics
An AI-synthesized read of the highest-engagement posts about Audentes Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Audentes Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.